Furthermore tumor-expressed CXCL9 was shown to be crucial for immune control of murine cutaneous fibrosarcomas (54) while CXCL11 secretion by genetically modified mouse T cell lymphoma cells (EL4) led to increased infiltration of CD8+CXCR3+ T cells and subsequent tumor rejection (55). This evidence concerns the gene CXCL9 and neoplasm.